Tesamorelin and MOTS-c work together synergistically: tesamorelin helps mobilize and improve fat quality and mitochondrial capacity, while MOTS-c improves how efficiently mitochondria use the fuel, creating a supply-and-utilization synergy.

Mitochondrial health serves as the bridge between fat loss and performance, and effective peptide stacking requires combining interventions with different mechanisms, such as tesamorelin (growth hormone/IGF-1 pathway) and MOTS-c (AMPK/mitochondrial energy sensing pathway), which act through distinct but complementary pathways to enhance mitochondrial function.

Tesamorelin upregulates genes involved in oxidative phosphorylation across the electron transport chain and in fatty acid oxidation, leading to cellular-level metabolic remodeling that enhances fat burning efficiency at the mitochondrial level.

Tesamorelin independently increases fat density in visceral and subcutaneous adipose tissue, indicating improved fat quality with smaller adipocytes, better vascularization, reduced hypoxia, and decreased inflammation, independent of fat quantity changes.

Visceral fat is metabolically active tissue that disrupts insulin sensitivity and metabolic function, and tesamorelin reduces it through mechanisms that improve fat quality, muscle composition, and mitochondrial efficiency, leading to long-term metabolic resilience.